JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M111838200 on March 23, 2002

J. Biol. Chem., Vol. 277, Issue 22, 19439-19447, May 31, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/22/19439    most recent
M111838200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sano, H.
Right arrow Articles by Lienhard, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sano, H.
Right arrow Articles by Lienhard, G. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Insulin Receptor Substrate 4 Associates with the Protein IRAS*

Hiroyuki SanoDagger , Simon C. H. LiuDagger , William S. Lane§, John E. Piletz, and Gustav E. LienhardDagger ||

From the Dagger  Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire 03755, the § Microchemistry and Proteomics Analysis Facility, Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, and the  Departments of Psychiatry, Pharmacology, and Physiology, University of Mississippi Medical Center, Jackson, Mississippi 39216

Received for publication, December 12, 2001, and in revised form, March 12, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The insulin receptor substrates (IRSs) are key components in signaling from the insulin receptor, and consequently any proteins that interact with them are expected to participate in insulin signaling. In this study we have searched for proteins that interact with IRS-4 by identifying the proteins that coimmunoprecipitated with IRS-4 from human embryonic kidney 293 cells by microsequencing through mass spectrometry. A group of proteins was found. These included phosphatidylinositol 3-kinase, a protein previously identified as an IRS-4 interactor, and several proteins for which there was no previous evidence of IRS-4 association. One of these proteins, named IRAS, that had been found earlier in another context was examined in detail. The results from the overexpression of IRAS, where its amount was about the same as that of IRS-4, indicated that IRAS associated directly with IRS-4 and showed that the increased complexation of IRS-4 with IRAS did not alter the insulin-stimulated tyrosine phosphorylation of IRS-4 or the association of IRS-4 with phosphatidylinositol 3-kinase or Grb2. On the other hand, overexpression of IRAS enhanced IRS-4-dependent insulin stimulation of the extracellularly regulated kinase. The domains of IRAS and IRS-4 responsible for the association of these two proteins were identified, and it was shown that IRAS also associates with IRS-1, IRS-2, and IRS-3.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The insulin receptor substrates (IRS)-1,1 IRS-2, IRS-3, and IRS-4 are a family of four similar proteins that play a key role in signaling from the insulin receptor (reviewed in Ref. 1). The activated insulin receptor phosphorylates each IRS on multiple tyrosine residues. The tyrosine-phosphorylated form of the IRS then binds to various SH2 domain-containing signaling proteins. These include the lipid kinase PI 3-kinase and the linker protein Grb2, which is complexed with Sos, the guanine nucleotide exchanger for Ras. Association of the IRS with PI 3-kinase stimulates its activity, and the resulting elevation of the lipid PI 3,4,5-trisphosphate leads to activation of Akt kinases. Association of the IRS with the Grb2-Sos complex enhances guanine nucleotide exchange on Ras, and the resulting elevation of the GTP form of Ras leads to activation of ERK kinases. The stimulation of PI 3-kinase is a required part of the signal transduction pathway to many of the cellular effects of insulin (2). The architecture of each IRS consists of an amino-terminal PH and PTB domain and a large carboxyl-terminal region with the sites of tyrosine phosphorylation. The PTB domain binds directly to the activated insulin receptor, and both the PH and PTB domains are required for efficient tyrosine phosphorylation of the IRS.

In an effort to identify additional proteins involved in insulin signaling, we and others have searched for proteins that associate with the IRSs. To date three approaches have been taken. First, proteins that were expected to interact with an IRS for various reasons have been selected, and their association with the IRS has been examined, generally by means of immunoprecipitation and immunoblotting (1, 3-7). Second, expression libraries have been screened with recombinant IRS (8-11). Third, yeast two-hybrid screens have been performed with portions of the IRS as bait (12, 13). These approaches have been mainly applied to IRS-1 and IRS-2 and have yielded a number of IRS-interacting proteins (1, 3-13).

In the present study, we have searched for proteins that interact with IRS-4 by another method, that of coimmunoprecipitation with IRS-4 followed by separation of the associated proteins by SDS-PAGE and microsequencing of them by mass spectrometry. An advantage of this method over the screening of expression libraries and the yeast two-hybrid screen is that it provides a direct display of all of the main IRS-associated proteins and their relative amounts in the cell type of interest. We chose IRS-4 in HEK293 cells for examination because less was known about the proteins that interact with IRS-4 and because IRS-4 is very abundant in this cell type (14).

Using this approach, we have identified a group of proteins that coimmunoprecipitated with IRS-4 and are thus likely to interact with it. We selected one of these proteins, known as IRAS, for further study. The cDNA encoding IRAS had previously been cloned in a screen of an expression library with antisera raised against the receptor for imidazoline compounds and named IRAS for imidazoline receptor antisera selected (15). By itself IRAS may not be an imidazoline receptor, because expression of the protein in COS and Sf9 insect cells did not result in imidazoline binding (15). However, it is possible IRAS is part of an imidazoline receptor, because expression of IRAS in Chinese hamster ovary cells resulted in an increase in imidazoline-binding sites (15). In this study we provide evidence that full-length IRAS associates directly with IRS-4 and that this association does not affect insulin-stimulated tyrosine phosphorylation of IRS-4 or the binding of PI 3-kinase and Grb2 to IRS-4. However, overexpression of IRAS enhanced the activation of ERK by insulin.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies-- Antibodies were purchased from the following sources (listed with the catalog numbers in parentheses): PI 3-kinase (06-195), Tyr(P) (4G10-agarose, 16-101), IRS-1 (06-248), and IRS-2 (06-506) from Upstate Biotechnology, Inc.; Tyr(P) (RC20, horseradish peroxidase) from Transduction Laboratories; phosphorylated ERK1/2 (9101), phosphorylated Akt Thr308 (9275), and phosphorylated Akt Ser473 (9271) from New England BioLabs; ERK1/2 (93), Akt 1/2 (8312), Grb2 (255), IRS-2 (1555), and HA epitope tag (7392) from Santa Cruz Biotechnology; and the T7 epitope tag (69522-3) from Novagen. Affinity-purified rabbit antibodies against the carboxyl-terminal 16-aa peptide of IRS-4 and against aa 994-1197 of IRS-4 were the ones described in Ref. 14.

Four types of rabbit antibodies were generated against human IRAS. These were against an amino terminus peptide consisting of aa 7-21, a carboxyl-terminal peptide consisting of aa 1395-1412, the glutathione S-transferase fusion protein with the PX domain of IRAS (aa 10-125), and the glutathione S-transferase fusion protein with the acidic domain of IRAS (aa 559-705). Each antibody was affinity-purified on the immobilized peptide or glutathione S-transferase fusion protein, as described in Refs. 16 and 17. All four antibodies immunoblotted IRAS, but none was effective for immunoprecipitation (data not shown). Unless noted otherwise, all of the experiments using an antibody against IRAS were performed with the one against the carboxyl-terminal peptide because this antibody was most sensitive for immunoblotting.

Plasmids-- Human IRAS cDNA in pcDNA3.1 was as described in Ref. 15. The following were generous gifts: human IRS-4 cDNA with an amino-terminal HA epitope tag in pCEFL (18) from Dr. Derek LeRoith; SRHis vector, which places His6, T7, and Xpress tags at the amino terminus of cDNA inserts (19) from Dr. Shigeo Ohno; mouse IRS-1 with a Myc tag at its carboxyl terminus (20) from Dr. Bryan Wolf; mouse IRS-2 in pCMVhis (21) from Dr. Xiao Sun; and rat IRS-3 with an HA tag at its amino terminus (22) from Dr. Takashi Kadowaki. DNA fragments encoding the PH-PTB domain (aa 74-339) and the carboxyl-terminal region (aa 331-1257) of IRS-4 were amplified by PCR with 5' primers containing a BamHI site and 3' primers without a restriction site. These were ligated into the SRHis vector at the BglII site and the KpnI site that was blunt ended with T7 polymerase. Similarly, DNA fragments encoding the PX domain (aa 1-127), an amino-terminal portion (aa 126-604), the acidic domain (aa 559-705), and the carboxyl-terminal region (aa 685-1504) of IRAS were amplified by PCR and ligated into the BglII/KpnI site of the SRHis vector. The plasmids encoding the pieces of IRS-4 and IRAS each generated a T7 epitope-tagged protein of the expected size (see Fig. 11B).

Cell Culture, Transfection, Lysis, and Fractionation-- HEK293 cells were grown on 10- or 3.5-cm plates in Dulbecco's modified Eagle's medium supplemented with 10% bovine fetal serum, 100 µg/ml streptomycin, and 100 units/ml penicillin. The medium was changed every other day, and the cells were used upon reaching confluence.

To generate HEK293 cells overexpressing IRAS, the cells were transfected with the human IRAS plasmid by means of the LipofectAMINE reagent (Invitrogen) according to the manufacturer's instructions. Stable transfectants were selected and subcloned with 0.8 mg/ml G418. Transfected cell lines were screened for expression of IRAS by immunoblotting. Two lines, one overexpressing IRAS by about 7-fold (designated D5) and another overexpressing it by about 4-fold (designated A2) (see Fig. 3), were selected for experiments. The transfected lines were cultured as described above with the exception that 0.8 mg/ml G418 was included in the medium.

For transient transfection, HEK293F cells, which is a subline of HEK293 cells, or Cos7L cells, both of which were purchased from Invitrogen, were used, because the efficiency of transfection of each cell type with the LipofectAMINE 2000 reagent is 99% (Invitrogen literature). The HEK293F cell line and our HEK293 cell line contained the same amounts of IRS-4 and IRAS as assessed by immunoblotting for these proteins (data not shown). The cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and transfected with 0.5 or 1 µg of plasmid for 3.5-cm plates and 5 µg for 10-cm plates with the LipofectAMINE 2000 reagent according to the manufacturer's instructions. For experiments on ERK activation, the cells were transfected at about 50% confluence and were used for experiments a day later when they were about 90% confluent. For other experiments transfection was performed with cells at about 90% confluence, and cells were used a day later.

For use in experiments the cells were serum-starved in Dulbecco's modified Eagle's medium containing 1 mg/ml bovine serum albumin for a period of 45 min and then left untreated or treated with 1 µM insulin (Humulin R, Lilly) for the time periods stated in the figure legends. For immunoprecipitations, the cells were then rinsed with phosphate-buffered saline and solubilized at 4 °C in lysis buffer (150 mM NaCl, 1 mM EDTA, 40 mM Hepes, pH 7.4) containing either 1.5 or 3% C12E9 detergent (Thesit; Roche Molecular Biochemicals), plus protease inhibitors (1 µM phenylmethanesulfonyl fluoride, 10 µM leupeptin, 1 µM pepstatin, 10 µM EP475, 10 µg/ml aprotinin) and phosphatase inhibitors (10 mM sodium pyrophosphate, 10 mM sodium fluoride, 1 mM sodium vanadate). Each 10-cm plate was lysed with 3 ml of buffer containing 1.5% C12E9 in the smaller scale immunoprecipitations for immunoblotting or with 1 ml of lysis buffer containing 3% C12E9 in the immunoprecipitations for microsequencing. The lysates were cleared by centrifugation. For direct immunoblotting of whole cell lysates, 35-mm plates of cells were scrapped into 0.5 ml of SDS sample buffer (4% SDS, 20 mM dithiothreitol, 10% glycerol, 0.004% bromphenol blue, 1 mM EDTA, 90 mM Tris, pH 6.8, with the same protease and phosphatase inhibitors as given above); the samples were held at 100 °C for 5 min and then passed through a 23-gauge needle to shear the DNA. The protein concentrations of the C12E9 and SDS lysates were measured by a precipitating Lowry assay (23). A 10-cm plate of HEK293 cells contained ~7 mg of protein.

The cells were fractionated exactly as described in Ref. 14. In brief, the cells were broken by passage through a Balch homogenizer, the cytosol and organelles were separated by centrifugation, the organelles were solubilized in C12E9, and the solubilized proteins were separated from insoluble material by centrifugation.

Identification of Proteins Coimmunoprecipitating with IRS-4-- Initially the proteins that coimmunoprecipitated with IRS-4 were examined on a small scale. Cleared lysate (0.5 ml of a lysate in 3% C12E9 containing half of a 10-cm plate) was incubated with 5 µg of antibody against the carboxyl terminus of IRS-4 or with irrelevant IgG at 4 °C for 2 h, and the immunoadsorbates were collected on Pansorbin (5 µl; Calbiochem) or protein A-Sepharose (20 µl; Amersham Biosciences) for 2 h. The beads were washed three times with lysis buffer containing 0.3% C12E9. The immunoprecipitates were solubilized either by holding the beads at 100 °C for 5 min in SDS sample buffer containing 20 mM dithiothreitol (reduced samples) or by mixing at room temperature with SDS sample buffer containing 8 M urea instead of dithiothreitol (nonreduced samples). The SDS samples were separated by SDS-PAGE on gradient gels of 5-12% and 5-15% for the reduced and nonreduced samples, respectively, together with known amounts of standard proteins (Bio-Rad). The separated proteins were electrophoretically transferred to nitrocellulose at 200 mA for 16 h in 25 mM Tris, 190 mM glycine, 20% methanol, 0.005% SDS. The nitrocellulose was stained with colloidal gold total protein stain (Bio-Rad).

To isolate the coimmunoprecipitating proteins for microsequencing, the cleared lysate in 3% C12E9 derived from ten 10-cm plates of HEK293 cells was incubated with 50 µg of antibody against IRS-4 or of irrelevant IgG. The immunoprecipitates were collected on 50 µl of protein A-Sepharose, the beads were washed five times, and the proteins were released with 150 µl of SDS sample buffer under reducing or nonreducing conditions. The SDS samples were separated by SDS-PAGE, and the gel was stained with Coomassie Brilliant Blue R-250 (Bio-Rad). The protein bands that were present in the IRS-4 immunoprecipitate but not in the immunoprecipitate with the irrelevant IgG were excised from the gel for sequence analysis.

The protein bands were subjected to in-gel reduction, carboxylamidomethylation, and tryptic digestion (Promega). Multiple peptide sequences were determined in a single run by microcapillary reverse-phase chromatography directly coupled to a Finnigan LCQ quadrupole ion trap mass spectrometer equipped with a custom nanoelectrospray source. The column was packed in-house with 5 cm of C18 support into a New Objective one-piece 75-µm-internal diameter column terminating in a 8.5-µm tip. The flow rate was 190 nl/min. The ion trap was programmed to acquire successive sets of three scan modes consisting of full scan mass spectroscopy (MS) over alternating ranges of 395-800 m/z or 800-1300 m/z, followed by two data-dependent scans on the most abundant ion in those full scale scans. These data-dependent scans allowed the automatic acquisition of a high resolution (zoom) scan to determine charge state and exact mass and MS/MS spectra for peptide sequence information. MS/MS spectra were acquired with a relative collision energy of 30% and an isolation width of 2.5 Da, and recurring ions were dynamically excluded. Interpretation of the resulting MS/MS spectra of the peptides was facilitated by programs developed at the Harvard Microchemistry Facility and by data base correlation with the algorithm Sequest (24, 25).

Immunoprecipitation and Immunoblotting-- The cleared lysate in 1.5% C12E9 (typically 1 ml containing 1.5 mg of protein) was incubated at 4 °C for 2 h with antibody of interest (typically about 5 µg). The immunoprecipitates were collected on protein A-Sepharose or protein G-Sepharose (20 µl) for 2 h, the beads were washed three times with lysis buffer containing 0.3% C12E9, and the proteins were released by heating with SDS sample buffer at 100 °C for 5 min.

The proteins were separated by SDS-PAGE and transferred electrophoretically to Immobilon-P (Millipore). The blots were blocked with 3% bovine serum albumin in TBST (150 mM NaCl, 0.3% Tween 20, 20 mM Tris, pH 7.6), incubated with primary antibody in TBST with 0.2% albumin, washed with TBST, incubated with horseradish peroxidase conjugate to antibody against the primary antibody (Bio-Rad) in TBST with 0.2% albumin, and washed. The purchased antibodies were used at dilutions recommended by the manufacturers; the antibodies against IRS-4 and IRAS were used at 4 and 10 µg/ml, respectively. The reactive proteins were then detected with enhanced chemiluminescence reagent (SuperSignal; Pierce). Each blot contained lanes with several different dilutions of a sample that gave a strong signal with the 1× load. These provided an internal measure of signal intensity versus the relative amount, which was used to estimate the relative amounts in the other lanes by visual comparison. In our experience this method of quantitation gives values that are the same as those obtained by densitometry of the autoradiograms.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteins Coimmunoprecipitating with IRS-4-- To find proteins that interact with IRS-4, we immunoprecipitated IRS-4 from lysates of HEK293 cells with an antibody against the carboxyl terminus of the protein and analyzed for associated proteins by SDS-PAGE and protein staining. Because the relatively large amount of the precipitating antibody stained strongly and obscured other proteins in the same size range, the immunoprecipitates were examined both under reducing conditions, where the heavy and light chains of the antibody ran at ~50 and 25 kDa, and under nonreducing conditions, where the intact antibody ran at about 130 kDa. As shown in Fig. 1, a number of proteins, ranging in size from 30 kDa to greater than 200 kDa, were present in the IRS-4 immunoprecipitate but not the control immunoprecipitate. One protein at 66 kDa that was identified as heat shock protein 70 (see below) was present in both but appeared more abundant in the IRS-4 immunoprecipitate. In a similar experiment, the proteins that coimmunoprecipitated with IRS-4 from lysates of HEK293 cells treated with insulin for 10 min were compared with those associated in the unstimulated state under reducing conditions. No difference in the associated proteins was detected (data not shown).


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 1.   Proteins associated with IRS-4 in HEK293 cells. Lysates of HEK293 cells were immunoprecipitated with antibody against IRS-4 (lanes 1 and 3) or with irrelevant rabbit IgG (lanes 2 and 4). The immunoprecipitated proteins were either reduced (lanes 1 and 2) or not (lanes 3 and 4) in SDS sample buffer, separated by SDS-PAGE, transferred to nitrocellulose, and stained for protein with colloidal gold, as described under "Experimental Procedures." Each immunoprecipitate was derived from 2 mg of lysate protein. The recovery of IRS-4 from the immunoprecipitate under nonreducing conditions was much lower (lane 3), and the fainter bands of it and the 14-3-3 proteins did not reproduce well. Presumably because of the low recovery of IRS-4 under nonreducing conditions, the less abundant IRAS was not seen in lane 3. A repetition of this experiment yielded similar results. The identity of each band, as determined by microsequencing of a larger scale preparation, is indicated.

To identify the proteins coimmunoprecipitating with IRS-4, the immunoprecipitation was carried out on a larger scale. The associated proteins at 200, 130, 116, 110, 97, 85, 66, 32, and 31 kDa were analyzed by ion trap tandem mass spectrometry as described under "Experimental Procedures." Table I summarizes the results of this analysis. These protein bands were identified as: IRAS, a deubiquitinating enzyme, a WD repeat protein, a mixture of the catalytic subunit of PI 3-kinase and a fragment of IRS-4, another fragment of IRS-4, a mixture of the regulatory subunit of PI 3-kinase and heat shock protein 90, heat shock protein 70, 14-3-3epsilon protein, and a mixture of 14-3-3 beta  and zeta  proteins, respectively.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Proteins coimmunoprecipitating with IRS-4

Association of IRAS with IRS-4-- We decided to investigate the interaction of the protein IRAS with IRS-4, because the limited information about IRAS suggested that it might be an interesting signaling protein. IRS-4 was immunoprecipitated from lysates of untreated and insulin-treated HEK293 cells, and the immunoprecipitates, lysates, and depleted lysates were immunoblotted for IRAS, IRS-4, and Tyr(P). Approximately 90% of the IRS-4 was depleted from the lysate by immunoprecipitation, and approximately the same percentage of the IRAS coimmunoprecipitated with the IRS-4 (Fig. 2A, compare lanes 11 and 12 versus lanes 5-10). The depleted IRS-4 and IRAS were recovered in the immunoprecipitates (lanes 1 and 2), and insulin treatment had no effect on the amount of IRAS that coimmunoprecipitated with IRS-4 (lanes 1 and 2). Control immunoprecipitations with irrelevant rabbit immunoglobulin yielded no IRS-4 or IRAS (lanes 3 and 4). To be certain that insulin treatment was effective, the samples were blotted for Tyr(P). As expected from our previous study (14), insulin treatment markedly increased the Tyr(P) content of IRS-4 (compare lane 1 with lane 2 and lanes 5-7 with lanes 8-10). No tyrosine phosphorylation of IRAS was detected.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 2.   Coimmunoprecipitation of IRAS with IRS-4. A, lysates of untreated or insulin-treated (10 min) HEK293 cells were immunoprecipitated with antibody against IRS-4 or irrelevant rabbit immunoglobulin (rIgG). The immunoprecipitates (IP), lysates (Lys), and lysates after immunoprecipitation (depleted lysates, dLys) were immunoblotted (IB) for IRAS, IRS-4, and Tyr(P), as described under "Experimental Procedures." The 1× load was derived from 1 mg of cell lysate. A repetition of this experiment gave similar results. B, Cos7L cells (10-cm plates) were transiently transfected with 4 µg each of plasmids encoding IRAS and control vector pcDNA 3.1 (lanes 1 and 3) or 4 µg each of plasmids encoding IRAS and HA-tagged IRS-4 (lanes 2 and 4). The cells were lysed in nonionic detergent, and a portion of each lysate was immunoprecipitated with anti-HA. Samples of the immunoprecipitates (IP) and lysates (Lys) were immunoblotted for IRAS and IRS-4. The 1× load is equivalent to 100 µg of lysate protein.

The results presented above do not exclude the possibility that rather than being associated with IRS-4, IRAS was directly immunoprecipitated by the antibody against IRS-4. To exclude this possibility, we first attempted to determine whether IRS-4 coimmunoprecipitated with antibody against IRAS. Unfortunately, neither the antibody against a peptide from the carboxyl end of IRAS that was routinely used for immunoblotting nor three other affinity-purified antibodies against other regions of IRAS (see "Experimental Procedures") were effective in immunoprecipitation. However, further evidence for the association of IRAS with IRS-4 was obtained by showing that immunoprecipitation of IRS-4 with two other antibodies, one against a glutathione S-transferase fusion protein with aa 994-1197 of IRS-4 and the other against Tyr(P) (4G10-agarose), resulted in the coimmunoprecipitation of IRAS (data not shown). Moreover, we have coexpressed HA-tagged IRS-4 and IRAS in Cos7L cells through transient transfection, immunoprecipitated the IRS-4 with anti-HA antibody from lysate of these cells and found by immunoblotting that the immunoprecipitate contained IRAS as well as IRS-4 (Fig. 2B).

Overexpression of IRAS-- The actual amount of IRAS that coimmunoprecipitated with IRS-4 from a lysate of HEK293 cells was ~<FR><NU>1</NU><DE>8</DE></FR> the amount of IRS-4, as assessed by protein staining either with colloidal gold or Coomassie Blue in comparison with known amounts of protein standards (Fig. 1 and data from preparative gel not shown). To examine the effect of more fully complexing IRS-4 with IRAS, we generated stably transfected lines of HEK293 cells that overexpressed IRAS, together with a control line containing vector only. Two of the IRAS-overexpressing lines, designated D5 and A2, were selected for study. The D5 and A2 lines expressed approximately seven and four times as much IRAS as the vector control HEK293 cells (Fig. 3A).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 3.   Overexpression of IRAS in HEK293 cells. HEK293 cells were stably transfected with IRAS cDNA or vector, as described under "Experimental Procedures." A, IRAS-overexpressing cell lines D5 and A2 and the vector control line were lysed in SDS sample buffer, and the lysates were immunoblotted for IRAS. The 1× load corresponds to 50 µg of protein. B, nonionic detergent lysates of the D5 and vector cell lines were immunoprecipitated with antibody against IRS-4; the immunoprecipitates were separated by SDS-PAGE, and the gel was stained with Coomassie Blue. The immunoprecipitates were derived from 3 mg of cell lysate. A repetition of these experiments gave similar results.

To examine the effect of overexpression of IRAS on the coimmunoprecipitation of proteins with IRS-4, we immunoprecipitated IRS-4 from the D5 and vector control lines and examined the immunoprecipitates by SDS-PAGE and Coomassie Blue staining under reducing conditions (Fig. 3B). The amounts of IRAS and IRS-4 in the immunoprecipitate from D5 cells were approximately the same, whereas in the immunoprecipitate from the vector control the amount of IRAS was much less than the amount of IRS-4. Thus, as expected, overexpression of IRAS resulted in most of the IRS-4 being associated with IRAS. In addition, it should be noted that overexpression of IRAS did not lead to an increase in the amounts of the other proteins in the IRS-4 immunoprecipitate. The relative amounts of these other proteins were about <FR><NU>1</NU><DE>5</DE></FR> or less of the amounts of IRAS and IRS-4, as assessed by protein staining (Figs. 1 and 3B). The fact that IRAS was the only protein in the IRS-4 immunoprecipitate from D5 cells present in an amount equivalent to IRS-4 indicates that IRAS associated directly with IRS-4 rather than through a third protein.

Subcellular Distributions of IRAS and IRS-4-- Untreated and insulin-treated HEK293 cells overexpressing IRAS (D5 line) or containing vector were fractionated into cytosol and total organelles. The latter fraction was solubilized with nonionic detergent to yield solubilized membranes and a pellet that consists largely of nuclei and cytoskeleton. In agreement with our previous results (14), IRS-4 was located in all three fractions in roughly equal amounts (Fig. 4). Neither insulin treatment nor overexpression of IRAS altered the distribution of IRS-4. Moreover, overexpression of IRAS did not change the amount of IRS-4 in HEK293 cells. With both the vector and the D5 lines, the subcellular distribution of IRAS was coincident with that of IRS-4. In the experiments shown in Fig. 4, insulin treatment was for 2 min. The subcellular distributions of IRS-4 and IRAS were also compared for normal HEK293 cells in the untreated state and after 10 min of exposure to insulin. The distributions were similar to those in Fig. 4, and insulin treatment resulted in no change (data not shown).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Subcellular distributions of IRAS and IRS-4. Untreated and insulin-treated (2 min) HEK293 cells overexpressing IRAS (D5) or the vector control cells were fractionated as described under "Experimental Procedures." The whole cell lysate (Lys), cytosol (cyt), detergent-solubilized membranous organelles (mem), and detergent-insoluble pellet (pel) were immunoblotted for IRAS and IRS-4. The load for each lane was the amount derived from 90 µg of whole cell lysate. A similar experiment in which the distributions of IRAS and IRS-4 in untransfected HEK293 cells were examined gave similar results. IB, immunoblot.

Effect of IRAS on Tyrosine Phosphorylation of IRS-4-- The effect of IRAS overexpression on the insulin-stimulated tyrosine phosphorylation of IRS-4 in the HEK293 cells was examined. The cells of the D5 and vector lines were untreated or treated with insulin for various times, lysed in SDS sample buffer, and immunoblotted for Tyr(P) (Fig. 5). The intensity of tyrosine phosphorylation in the basal state was the same in the two lines. Insulin treatment resulted in a 4-fold increase in phosphorylation within 2 min that persisted for at least 1 h. Overexpression of IRAS had no effect on the time course or extent of insulin-stimulated IRS-4 phosphorylation. Reprobing the membrane for IRS-4 again showed that the amount of IRS-4 was almost the same in the D5 and vector lines. Similar results were obtained in an experiment comparing the tyrosine phosphorylation of IRS-4 in the A2 and vector lines.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of IRAS overexpression on tyrosine phosphorylation of IRS-4. D5 and vector HEK293 cells were treated with insulin for the stated periods and then solubilized in SDS sample buffer. Samples containing 50 µg of protein were immunoblotted for Tyr(P) and IRS-4. A repetition of this experiment gave similar results. IB, immunoblot.

Effect of IRAS on IRS-4 Signaling Complexes-- We have previously shown that IRS-4 associates with PI 3-kinase and Grb2 in HEK293 cells (14). Although overexpression of IRAS did not alter tyrosine phosphorylation of IRS-4, it seemed possible that it might affect the formation of the complexes between IRS-4 and these signaling proteins. To investigate this possibility, IRS-4 was immunoprecipitated from lysates of unstimulated and insulin-treated HEK293 D5 and vector cells, and the immunoprecipitates were immunoblotted for the 85-kDa subunit of PI 3-kinase and Grb2, as well as for IRAS and IRS-4 (Fig. 6A). As we had found previously (14), PI 3-kinase was associated with IRS-4 in both the unstimulated and insulin-treated state, presumably because in HEK293 cells IRS-4 contains some Tyr(P) in the untreated state. On the other hand insulin stimulated the association of Grb2 with IRS-4. Overexpression of IRAS had no significant effect on the association of either PI 3-kinase or Grb2 with IRS-4, even though, as expected, it resulted in approximately seven times as much IRAS present in the IRS-4 immunoprecipitate.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   Complex formation with IRS-4. Lysates of untreated and insulin-treated (2 min) D5 and vector HEK293 cells were immunoprecipitated with antibodies against IRS-4 (A), PI 3-kinase (B), and Grb2 (C), as described under "Experimental Procedures." The immunoprecipitates (IP) were immunoblotted (IB) for IRAS, IRS-4, PI 3-kinase, and Grb2. The 1× load was derived from 0.4 mg of lysate protein. A repetition of this experiment gave similar results. The signal for PI 3-kinase is a doublet, which may be due to the presence of both the alpha  and beta  isotypes of the 85-kDa subunit. The slight increase in the amount of PI 3-kinase associated with IRS-4 in response to insulin (~25%) seen in A (first and second lanes) was not observed in the replicate experiment.

PI 3-kinase and Grb2 are considered to bind directly to IRS-4 through interaction of their SH2 domains with specific Tyr(P) motifs on IRS-4 (14). Consequently, the coimmunoprecipitation of IRAS, PI 3-kinase, and Grb2 with IRS-4 could be due to the formation of binary complexes of each protein with IRS-4, to the formation of ternary complexes of IRS-4 with IRAS and either PI 3-kinase or Grb2, and/or to the formation of a quarternary complex of all four proteins. To determine whether such a quarternary complex formed and if so how overexpression of IRAS affected it, we immunoprecipitated PI 3-kinase and Grb2 from lysates of unstimulated and insulin-treated HEK293 D5 and vector cells and immunoblotted the immunoprecipitates for IRAS, IRS-4, PI 3-kinase, and Grb2. As shown in Fig. 6B, the PI 3-kinase immunoprecipitate contained IRAS, IRS-4, and Grb2. This finding indicates that a quarternary complex of the four proteins occurs. In agreement with the results from the immunoprecipitation of IRS-4, the amounts of IRAS and IRS-4 in the PI 3-kinase immunoprecipitate were increased only very slightly by insulin treatment, whereas the amount of Grb2 in the immunoprecipitate was increased markedly by insulin treatment. Overexpression of IRAS resulted in the expected increase of ~7-fold of IRAS in the PI 3-kinase immunoprecipitate but had no effect on the amounts of IRS-4 and Grb2 in the complex.

The composition of the Grb2 immunoprecipitates also indicated the formation of a quarternary complex (Fig. 6C). IRAS, IRS-4, and PI 3-kinase coimmunoprecipitated with Grb2, and insulin treatment markedly enhanced the amounts of all three proteins in the Grb2 immunoprecipitate to the same extent. Overexpression of IRAS increased the amount of IRAS in the Grb2 immunoprecipitates but did not alter the amounts of IRS-4 and PI 3-kinase. Immunoblotting of the lysates used for immunoprecipitation showed that the HEK293 D5 and vector lysates contained the same amounts of PI 3-kinase and Grb2 (data not shown).

As described above, the relative amounts of the proteins in the IRS-4 immunoprecipitate from D5 cells indicated that IRAS does not associate directly with PI 3-kinase or Grb2. In the case of Grb2, this possibility can also be excluded because the amount of Grb2 coimmunoprecipitating with IRS-4 increased with insulin treatment, whereas the amount of IRAS did not (Fig. 6A). A similar argument cannot be made in the case of PI 3-kinase, because insulin treatment only slightly enhanced the association of PI 3-kinase with IRS-4. However, we have found by immunoblotting that immunoprecipitation of 90% of the IRS-4 from a lysate of HEK293 cells coimmunoprecipitated ~90% of the IRAS, whereas immunoprecipitation of 90% of the PI 3-kinase resulted in coimmunoprecipitation of less than 25% of the IRAS (Fig. 2 and data not shown). This result also indicates that IRAS does not bind directly to PI 3-kinase.

Effect of IRAS on Activation of Kinases-- Even though overexpression of IRAS had no effect on insulin-stimulated tyrosine phosphorylation of IRS-4 or on complex formation with IRS-4, it seemed possible that it might effect the insulin activation of the ERK or Akt kinases. Activation of the ERK1/2 was examined by immunoblotting SDS lysates of untreated and insulin-treated cells with antibody specific for the phosphorylated, activated form. Insulin treatment caused the rapid appearance of the phosphorylated form of ERK1/2 (Fig. 7). The extent of ERK1/2 activation, as assessed by the intensity of the signal, was approximately four times greater in the D5 line of HEK293 cells than in the vector line (Fig. 7, lane 2 versus lane 7) and approximately two times greater in the A2 line than in the vector line (Fig. 7, lane 9 versus lane 7). The larger effect in the D5 line than the A2 line correlates with the greater extent of overexpression of IRAS in the D5 line (Fig. 3). All three lines expressed approximately the same amount of ERK1/2 (Fig. 7). These comparisons were made with cells treated for 2 min with insulin, because immunoblotting SDS samples of D5 and vector cells for phosphorylated ERK1/2 treated with insulin for various times showed that phosphorylation was maximal at this time and returned to near basal level in 60 min (data not shown).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of stable IRAS overexpression on insulin activation of ERK in HEK293 cells. D5 and vector HEK293 cells were left untreated or treated with insulin for 2 min and dissolved in SDS sample buffer. The samples were immunoblotted for phosphorylated ERK1/2 (pERK) and for ERK1/2. The 1× load corresponds to 50 µg of protein. A repetition of this experiment gave similar results.

To determine whether the effect of IRAS overexpression on insulin activation of ERK1/2 was dependent upon the association of IRAS and IRS-4, we examined ERK1/2 activation in Cos7L cells, which normally contain no IRAS and little or no IRS-4, upon expression of IRAS, IRS-4, or both through transient transfection. Expression of the combination of IRAS and IRS-4 resulted in ~4-fold enhancement of insulin activation of ERK1/2 (Fig. 8, compare lanes 2 and lane 8), whereas expression of either IRAS or IRS-4 alone had little or no effect on insulin activation of ERK1/2 (Fig. 8, compare lane 2 and lane 4 or 6). The requirement of both IRAS and IRS-4 for enhancement of insulin activation of ERK1/2 strongly suggests that this enhancement is dependent upon their association. Further evidence for a role of IRAS in specifically augmenting insulin activation of ERK1/2 was obtained by comparing the effect of its overexpression in HEK293F cells by transient transfection upon insulin and EGF activation of ERK1/2. As expected from the results of stable transfection of HEK293 cells, overexpression of IRAS enhanced insulin activation of ERK1/2 (Fig. 9A, compare lane 2 and lane 4). However, it had no effect on EGF activation of ERK1/2 (Fig. 9B, compare lane 2 and lane 4).


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of transient IRAS and IRS-4 expression on insulin activation of ERK1/2 in Cos7L cells. Cos7L cells in 3.5-cm wells were transfected with 0.5 µg of plasmid encoding IRAS, IRS-4, or a combination of both. The total amount of plasmid was maintained at 1 µg throughout with pcDNA3.1 vector. The cells were treated with insulin or not for 2 min and then solubilized in SDS sample buffer, and the samples were immunoblotted for phosphorylated ERK1/2 (pERK), ERK1/2, IRAS, and IRS-4. The 1× load corresponds to 3% of a 3.5-cm plate of cells for ERK1/2 and 1% of a plate for the other proteins. A repetition of this experiment gave similar results.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of transient IRAS overexpression on insulin and EGF activation of ERK in HEK293F cells. HEK293F cells were transiently transfected with IRAS. The cells were treated with insulin (A) or with 10 nM EGF (B) for 2 min and solubilized in SDS sample buffer. The samples were immunoblotted for ERK1/2 (pERK) and for ERK1/2. The 1× load corresponds to 50 µg of protein. A repetition of this experiment gave similar results.

Activation of Akt1/2 in the control and IRAS-overexpressing D5 HEK293 lines was examined by immunoblotting with antibodies specific for the phosphorylated Thr and Ser on the activated kinases, which are designated Thr308 and Ser473 for their locations on Akt 1. In this case immunoblotting SDS lysates yielded blots that were too messy for interpretation, and consequently we immunoprecipitated the Akt from lysates and then immunoblotted the immunoprecipitates. Untreated cells contained the phosphorylated forms of Akt; insulin treatment caused an ~1.5-fold increase in the phosphorylation of Akt Thr308 and a lesser increase in the phosphorylation of Akt Ser473 (Fig. 10). The IRAS-overexpressing D5 line showed the same degree of Akt phosphorylation on each site as the vector-transfected line in both the untreated and insulin-treated states. Reprobing of the blots for Akt1/2 showed that the two cell lines expressed the same amounts of Akt.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 10.   Effect of stable IRAS overexpression on insulin activation of Akt in HEK293 cells. D5 and vector HEK293 cells were treated or not with insulin for 2 min and solubilized in nonionic detergent. The cleared lysates were immunoprecipitated with antibody against Akt1/2, and the immunoprecipitates were immunoblotted for Akt1/2 phosphorylated on Thr308 and Ser473 (pThr and pSer). The immunoblots were then stripped and reprobed for Akt. The 1× load was derived from 0.3 mg of lysate. A repetition of this experiment, with the exception that the insulin treatment of the cells was for 5 min rather than 2 min, gave similar results. IB, immunoblot.

Domains of IRAS and IRS-4 That Interact-- To determine the region of IRAS that interacts with IRS-4, we coexpressed T7 epitope-tagged sections of IRAS with IRS-4 in Cos7L cells by transient transfection and examined the anti-T7 immunoprecipitates from cell lysates for IRS-4. IRAS contains a PX domain at its amino terminus and an acidic region in its middle (15). Consequently IRAS was divided into its PX domain, the acidic region, the region intervening between these two, and its carboxyl-terminal segment (Fig. 11A). Only the carboxyl-terminal segment of IRAS bound a significant amount of IRS-4 (Fig. 11B, left top panel). Immunoblotting of the lysates for the T7 epitope showed that the immunoprecipitates contained about equal amounts of the four IRAS sections (Fig. 11B, left bottom panel). In a similar fashion, to determine the portion of IRS-4 that interacts with IRAS, the combined PH and PTB domains at the amino terminus of IRS-4 (PH-PTB) (23) and the carboxyl-terminal section of IRS-4 (C-IRS4) (Fig. 11A) were coexpressed with IRAS. In this case, IRAS coimmunoprecipitated mainly with C-IRS4 (Fig. 11B, right top panel). There was also a small amount of IRAS in the immunoprecipitate of the PH-PTB portion that was not detected in the immunoprecipitate with a control immunoglobulin (Fig. 11B, right top panel, compare IgG and PH-PTB).


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 11.   Interacting regions of IRAS and IRS-4. A, schematic diagrams of the structures of IRAS and IRS-4. B, coimmunoprecipitation with parts of IRAS or IRS-4. T7 epitope-tagged regions of IRAS or IRS-4 were coexpressed with IRS-4 or IRAS, respectively, in Cos7L cells. Detergent lysates of the cells were immunoprecipitated with anti-T7 antibody. The lysate with PH-PTB and IRAS was also immunoprecipitated with control immunoglobulin (IgG). Amounts of the immunoprecipitates containing approximately equal amounts of the T7 epitope-tagged protein, as judged by immunoblotting with anti-T7 antibody (bottom panels) were immunoblotted for IRS-4 or IRAS (top panels). A repetition of this experiment gave similar results.

Association of IRAS with Other IRSs-- To assess whether IRAS could associate with other IRSs, we coexpressed IRAS and each of the IRSs in Cos7L cells. Each IRS protein was then immunoprecipitated from its cell lysate, and the immunoprecipitate was immunoblotted for IRAS. In each case IRAS coimmunoprecipitated with the IRS (Fig. 12, right panel). In an attempt to gauge the relative strength of the associations, we estimated the percentage of each IRS and of IRAS that was immunoprecipitated by comparing the signal of the immunoprecipitate with that of the various loads of the lysate (Fig. 12). When ~15% of IRS-1, 5% of IRS-2, and 5% of IRS-3 were immunoprecipitated, the immunoprecipitates contained 2, 0.8, and 1% of the IRAS, respectively. In contrast, when ~50% of the IRS-4 was immunoprecipitated, the immunoprecipitate contained 50% of the IRAS. Thus, the ratio of IRAS immunoprecipitated to IRS immunoprecipitated was ~10 times higher for IRS-4 than for the other three IRSs. Provided that the levels of expression of the four IRSs were similar and that the antibodies used for immunoprecipitation of IRS-1, IRS-2, and IRS-3 did not partially compete with IRAS for binding to the IRS, this finding suggests that the affinity of IRS-4 for IRAS is greater than that of the other IRSs. There is no simple way to ascertain whether the expression of the four IRSs was similar, but because expression of each was driven by the cytomegalovirus promoter, this may be the case. Similarly, there is no simple way to determine whether any of the anti-IRSs partially competed with IRAS for binding to the IRS, although as was the case for the antibody against IRS-4 used here, the antibodies against IRS-1 and IRS-2 were against the carboxyl terminus, and the antibody against IRS-3 was against the amino-terminal HA tag.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 12.   Association of IRAS with IRS-1, IRS-2, and IRS-3. IRAS was transfected into Cos7L cells together with IRS-1, IRS-2, IRS-3, or IRS-4. Detergent lysates of the cells were immunoprecipitated with antibodies against the carboxyl terminus of IRS-1, IRS-2, or IRS-4 or with anti-HA for epitope-tagged IRS-3 and with control immunoglobulin. SDS samples of the IRS and control immunoprecipitates (IP and C, respectively) and the lysates (Lys) were immunoblotted for the IRS (left panel) and for IRAS (right panel). The relative loads are given below each lane; the 1× load corresponds to 1% of a 10-cm plate. A repetition of this experiment gave similar results.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study we have searched for novel proteins that may participate in insulin signaling by identifying proteins that coimmunoprecipitated with IRS-4. Because of the great sensitivity of peptide sequencing by ion trap mass spectrometry, this approach is entirely feasible. The validity of this approach was established by the identification of the catalytic and regulatory subunits of PI 3-kinase in the IRS-4 immunoprecipitate. Previously we had shown by immunoblotting that IRS-4 associates with PI 3-kinase in HEK293 cells (Ref. 14 and Fig. 6). Moreover, the identification of the 14-3-3 proteins in the IRS-4 immunoprecipitate is consistent with earlier studies showing that 14-3-3 proteins associate with IRS-1 and IRS-2 (4, 5, 10).

In addition to PI 3-kinase and the 14-3-3 proteins, the IRS-4 immunoprecipitate specifically contained a number of other proteins: IRAS, a deubiquitinating enzyme, a WD domain protein, and heat shock protein 90. In this study we focused on characterizing the interaction of IRAS with IRS-4. Additional studies will be required to determine whether the other proteins in the IRS-4 immunoprecipitate interact directly with IRS-4 or one of its associated proteins and, if so, what effects they have on IRS-4 function.

Several types of evidence strongly indicate that IRAS is associated with IRS-4. First, IRAS coimmunoprecipitated with IRS-4 using four different antibodies to immunoprecipitate IRS-4. Second, IRAS was present together with IRS-4 in the immunoprecipitates of PI 3-kinase and Grb2, two proteins known to associate directly with specific Tyr(P) motifs in the IRSs via their SH2 domains. Moreover, the association of IRAS and IRS-4 is almost certainly a direct one rather than one through a third protein, because in the IRS-4 immunoprecipitate from the D5 cell line IRAS was the only protein specifically present in an amount equivalent to IRS-4.

In normal HEK293 cells, almost all of the IRAS was complexed with IRS-4, but because the amount of IRAS was only about <FR><NU>1</NU><DE>8</DE></FR> that of the IRS-4, only a small fraction of the IRS-4 was complexed with IRAS. Consequently, to investigate the role of IRAS in IRS-4 signaling, we overexpressed IRAS so that its level was approximately the same as that of IRS-4, and most of the IRS-4 was complexed with IRAS. Overexpression of IRAS had no effect on the insulin-stimulated tyrosine phosphorylation of IRS-4. Moreover, it did not affect of the amounts of PI 3-kinase or Grb2 complexed with IRS-4 in the untreated or insulin-treated state. Overexpression of IRAS also had no effect on insulin activation of Akt, a kinase that is downstream of PI 3-kinase (2), as assessed by immunoblotting with phosphospecific antibodies. Untreated cells contained activated phosphorylated Akt, and there was only a small increase in its amount in response to insulin. The presence of activated Akt in untreated cells was probably due to constitutive activation of PI 3-kinase, because in untreated HEK293 cells the IRS-4 contained some Tyr(P) and was complexed with PI 3-kinase. The absence of an effect of overexpression of IRAS on Akt activation shows that it does not inhibit Akt activation. However, it is uncertain whether IRAS overexpression could enhance insulin-dependent Akt activation under the appropriate conditions, because it is not known whether Akt is fully activated in the insulin-treated normal HEK293 cells.

In contrast to the results with Akt, there was no detectable activated phosphorylated ERK in untreated HEK293 cells, and insulin treatment caused its activation. Moreover, overexpression of IRAS enhanced the insulin-stimulated activation of ERK by about 4-fold. Activation of ERK in response to insulin is initiated with the tyrosine phosphorylation of the IRSs and Shc by the activated insulin receptor. These proteins then bind Grb2, which is associated with Sos, the guanine nucleotide exchange protein for Ras. This association activates the exchange activity of Sos and so leads to an elevation of the GTP form of Ras, which in turn activates the mitogen-activated protein kinase cascade and thus results in activation of ERK (1). It remains to be determined how the overexpression of IRAS stimulated this signaling pathway. Overexpression of IRAS had no significant effect on the amounts of Grb2 or ERK in the cells, nor on the amount of Grb2 that associated with IRS-4 in response to insulin. The finding that the enhancement of insulin activation of ERK by IRAS in Cos7 cells required coexpression of IRS-4 indicates that the effect depends upon the association of IRAS with IRS-4. Moreover, the fact that EGF activation of ERK in HEK293F cells was not enhanced by IRAS overexpression is also consistent with this conclusion. EGF activation of ERK also proceeds via Shc, Ras, and the mitogen-activated protein kinase cascade (26). Thus, if IRAS were functioning by interaction with one of these components, it would be expected to enhance EGF activation of ERK as well. A possible explanation for the effect of IRAS on insulin activation of ERK is that the IRS-4-Grb2-Sos complex is more active in stimulating guanine nucleotide exchange on Ras when the complex also contains IRAS.

Through expression of the various parts of IRAS and IRS-4, it was found that the main interaction between these proteins occurs via the carboxyl-terminal region of each. In light of a previous study by Burks et al. (13), this finding was somewhat surprising. These authors employed the yeast two-hybrid system to identify proteins that interact with the PH domain of IRS-1 and IRS-2. They found several proteins, each of which contained an acidic domain, although IRAS was not one of them. They showed that these proteins associated with IRS-1 and IRS-2 through binding of the acidic domain to the PH domain. Thus, on the basis of this study, we expected to find the acidic domain of IRAS interacting with the PH domain of IRS-4. It remains possible that such an interaction also contributes to the association. IRAS also associates with IRS-1, IRS-2, and IRS-3, although our data suggest that it associates considerably more weakly with them than with IRS-4. Thus, with these other IRSs the main interaction could be between the acidic domain and the PH domain.

While this work was in progress, a study appeared in which a portion of IRAS was found to interact with integrin alpha 5 subunit by a screen in the yeast two-hybrid system (27). The study characterized a truncated version of IRAS without the PX domain at its amino terminus, which was named Nischarin. Overexpression of Nischarin caused reorganization of actin filaments and reduced cell migration dependent upon alpha 5beta 1 integrin. The relation of these effects to the association of IRAS with IRS-4 remains to be established.

In the future it will be important to determine the cellular role of IRAS. The fact that IRAS is highly expressed in the brain (28) and IRS-4 is strongly expressed in the hypothalamus (29) suggests that the association of the two may play a role in the hypothalamus. In addition it will be important to establish whether IRAS is a portion of the brain imidazoline receptor and, if so, whether the binding of an imidazoline affects the interaction of IRAS with IRS-4. In this regard, transfection of IRAS cDNA into Chinese hamster ovary cells has been reported to produce binding sites with nanomolar affinity for moxonidine, the ligand most selective for the I1 imidazoline receptor (15, 30). However, expression of IRAS in COS and Sf9 cells did not lead to an increase in binding sites (15), and the D5 and A2 cell lines overexpressing IRAS described here showed no change in the number or affinity of imidazoline binding sites.2

    ACKNOWLEDGEMENTS

We thank Valeria R. Fantin for preliminary experiments on IRS-4-interacting proteins, Kerry A. Pierce and Eric Spooner for technical assistance in the peptide sequencing, and Michael Chen for preparation of the plasmid containing IRAS cDNA.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK42816 (to G. E. L.) and MH49248 (to J. E. P.), a grant from the Uehara Memorial Foundation (to H. S.), and a grant from Solvay Pharmaceuticals Company (to J. E. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Dept. of Biochemistry, Vail Bldg., Dartmouth Medical School, Hanover, NH 03755. Tel.: 603-650-1627; Fax: 603-650-1128; E-mail: gustav.e.lienhard@dartmouth.edu.

Published, JBC Papers in Press, March 23, 2002, DOI 10.1074/jbc.M111838200

2 J. E. Piletz, unpublished data.

    ABBREVIATIONS

The abbreviations used are: IRS, insulin receptor substrate; aa, amino acid; EGF, epidermal growth factor; ERK, extracellularly regulated kinase; HEK, human embryonic kidney; PI, phosphatidylinositol; PH, pleckstrin homology; PTB, phosphotyrosine binding; HA, hemagglutinin; PX, phox; MS, mass spectroscopy.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. White, M. F. (1998) Rec. Prog. Hormone Res. 53, 119-138[Medline] [Order article via Infotrieve]
2. Shepherd, P. R., Withers, D. J., and Siddle, K. (1998) Biochem. J. 333, 471-490[Medline] [Order article via Infotrieve]
3. Munshi, H. G., Burks, D. J., Joyal, J. L., White, M. F., and Sacks, D. B. (1996) Biochemistry 35, 15883-15889[CrossRef][Medline] [Order article via Infotrieve]
4. Craparo, A., Freund, R., and Gustafson, T. A. (1997) J. Biol. Chem. 272, 11663-11669[Abstract/Free Full Text]
5. Kosaki, A., Yamada, K., Suga, J., Otaka, A., and Kuzuya, H. (1998) J. Biol. Chem. 273, 940-944[Abstract/Free Full Text]
6. Aguirre, V., Uchida, T., Yenush, L., Davis, R., and White, M. F. (2000) J Biol. Chem. 275, 9047-9054[Abstract/Free Full Text]
7. Ueno, H., Kondo, E., Yamamoto-Honda, R., Tobe, K., Nakamoto, T., Sasaki, K., Mitani, K., Furusaka, A., Tanaka, T., Tsujimoto, Y., Kadowaki, T., and Hirai, H. (2000) Mol. Biol. Cell 11, 735-746[Abstract/Free Full Text]
8. Sun, X. J., Pons, S., Asano, T., Myers, J., M. G., Glasheen, E., and White, M. F. (1996) J. Biol. Chem. 271, 10583-10587[Abstract/Free Full Text]
9. Algenstaedt, P., Antonetti, D. A., Yaffe, M. B., and Kahn, C. R. (1997) J. Biol. Chem. 272, 23696-23702[Abstract/Free Full Text]
10. Ogihara, T., Isobe, T., Ichimura, T., Taoka, M., Funaki, M., Sakoda, H., Onishi, Y., Inukai, K., Anai, M., Fukushima, Y., Kikuchi, M., Yazaki, Y., Oka, Y., and Asano, T. (1997) J. Biol. Chem. 272, 25267-25274[Abstract/Free Full Text]
11. VanRenterghem, B., Morin, M., Czech, M. P., and Heller-Harrison, R. A. (1998) J. Biol. Chem 273, 29942-29949[Abstract/Free Full Text]
12. Farah, S., Agazie, Y., Ohan, N., Ngsee, J. K., and Liu, X. J. (1998) J. Biol. Chem. 273, 4740-4746[Abstract/Free Full Text]
13. Burks, D. J., Wang, J., Towery, H., Ishibashi, O., Lowe, D., Riedel, H., and White, M. F. (1998) J. Biol. Chem. 273, 31061-31067[Abstract/Free Full Text]
14. Fantin, V. R., Sparling, J. D., Slot, J. W., Keller, S. R., Lienhard, G. E., and Lavan, B. E. (1998) J. Biol. Chem 273, 10726-10732[Abstract/Free Full Text]
15. Piletz, J. E., Ivanov, T. R., Sharp, J. D., Ernsberger, P., Chang, C. H., Pickard, R. T., Gold, G., Roth, B., Zhu, H., Jones, J. C., Baldwin, J., and Reis, D. J. (2000) DNA Cell Biol 19, 319-329[CrossRef][Medline] [Order article via Infotrieve]
16. Lamphere, L., and Lienhard, G. E. (1992) Endocrinology 131, 2196-2202[Abstract]
17. Keller, S. R., Scott, H. M., Mastick, C. C., Aebersold, R., and Lienhard, G. E. (1995) J. Biol. Chem. 270, 23612-23618[Abstract/Free Full Text]
18. Qu, B. H., Karas, M., Koval, A., and LeRoith, D. (1999) J. Biol. Chem 274, 31179-31184[Abstract/Free Full Text]
19. Akimoto, K., Takahashi, R., Moriya, S., Nishioka, N., Takayanagi, J., Kimura, K., Fukui, Y., Osada, S., Mizuno, K., Hirai, S., Kazlauskas, A., and Ohno, S. (1996) EMBO J. 15, 788-798[Medline] [Order article via Infotrieve]
20. Xu, G. G., Gao, Z., Borge, P. D., Jr., and Wolf, B. A. (1999) J. Biol. Chem 274, 18067-18074[Abstract/Free Full Text]
21. Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177[CrossRef][Medline] [Order article via Infotrieve]
22. Yamauchi, T., Kaburagi, Y., Ueki, K., Tsuji, Y., Stark, G. R., Kerr, I. M., Tsushima, T., Akanuma, Y., Komuro, I., Tobe, K., Yazaki, Y., and Kadowaki, T. (1998) J. Biol. Chem 273, 15719-15726[Abstract/Free Full Text]
23. Peterson, G. L. (1977) Anal. Biochem 83, 346-35620[CrossRef][Medline] [Order article via Infotrieve]
24. Eng, J. K., McCormick, A. L., and Yates, J. R. (1994) J. Am. Soc. Mass Spectrom 5, 976-989[CrossRef]
25. Chittum, H. S., Lane, W. S., Carlson, B. A., Roller, P. P., Lung, F. D., Lee, B. J., and Hatfield, D. L. (1998) Biochemistry 37, 10866-10870[CrossRef][Medline] [Order article via Infotrieve]
26. Bogdan, S., and Klambt, C. (2001) Curr. Biol 10, R292-R295
27. Alahari, S. K., Lee, J. W., and Juliano, R. L. (2000) J. Cell Biol 151, 1141-1154[Abstract/Free Full Text]
28. Ivanov, T. R., Jones, J. C., Dontenwill, M., Bousquet, P., and Piletz, J. E. (1998) J. Auton. Nerv. Syst. 72, 98-110[CrossRef][Medline] [Order article via Infotrieve]
29. Numan, S., and Russell, D. S. (1999) Mol. Brain Res 72, 97-102[Medline] [Order article via Infotrieve]
30. Piletz, J. E., and Sletten, K. (1993) J. Pharm. Exp. Ther. 267, 1493-1502[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg